ico_admin

iCo Therapeutics Announces Completion of Phase 1b Oral Amphotericin B Study Dosing & Follow Up

February 10, 2020, Vancouver, Canada - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo"

ico_admin2020-02-10T21:05:51+00:00February 10th, 2020|2020|

January 10, 2020, Vancouver, Canada — iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or

ico_admin2020-01-29T23:52:29+00:00January 10th, 2020|2020|

December 24, 2019, Vancouver, Canada — iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the

ico_admin2020-01-29T23:40:49+00:00December 24th, 2019|2019|

December 11, 2019, Vancouver, Canada — iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo"

ico_admin2020-01-29T23:42:07+00:00December 11th, 2019|2019|

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

ico_admin2019-07-16T17:12:54+00:00March 5th, 2019|2019|

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

ico_admin2019-07-04T04:27:32+00:00February 25th, 2019|2019|

February 19, 2019, Vancouver, Canada — iCo Therapeutics Inc. (“iCo” or “the Company”) (TSX-V:

ico_admin2019-07-04T04:26:17+00:00February 19th, 2019|2019|

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

ico_admin2019-07-04T04:24:33+00:00February 19th, 2019|2019|

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

ico_admin2019-07-04T04:24:52+00:00February 11th, 2019|2019|

January 31, 2019, Vancouver, Canada — iCo Therapeutics Inc. (“iCo” or “the Company”) (TSX-V:

ico_admin2019-07-03T21:27:57+00:00February 7th, 2019|2019|